Tom Murphy

Reporter

Tom Murphy
Tom Murphy
Reporter

I'm thrilled to join Eyewitness News and the best team in Kern County. Go easy on me though, I'm a long way from home.

Born and raised in Morristown, New Jersey, I'm an East Coast guy at heart. While I'm from the "Garden State," it hasn't been a garden variety journey to California.

In 2010, I started as an anchor, reporter and producer at WBKB in Alpena, Mich. In one of the smallest markets in the country, the running joke was WBKB stood for "We Barely Know Broadcasting." I was ready to get my shot at a long-time goal of being on air working in broadcasting. Alpena will always hold a special place in my heart, because it was a great place to grow and get my start. But I'm excited to say good-bye to snow and hello to Bakersfield.

Before shipping up to Alpena, I attended the University of Miami in Florida. I graduated from "The U" in May of 2010 with majors in broadcast journalism and English literature. While in the 305, I was an anchor for the award-winning "SportsDesk," as well as a reporter for the Emmy-nominated "Newsvision."

I'm proud to be a Miami Hurricane and can't wait for the Canes to contend in the ACC this year. I'm a sports fanatic and it's not just my alma mater. My teams are the New York Giants (Super Bowl champs), New Jersey Devils, New York Yankees (27 Titles and counting) and New York Knicks (we're working on it).

If you want to chat friend me on Facebook, follow me on Twitter @Tmurph2010, or email me tmurphy@bakersfieldnow.com.

Recent stories by Tom Murphy

Technology Icahn signs confidentiality agreement with Dell
By TOM MURPHY AP Business Writer Published: Mar 11, 2013 at 8:00 AM PDT
Billionaire investor Carl Icahn, who is fighting Dell Inc. founder Michael Dell's plan to take the struggling company private, has entered a confidentiality agreement that would give him access to the computer maker's financial records.
Health Lilly plans another study for Alzheimer's drug Lilly plans another study for Alzheimer's drug
By TOM MURPHY AP Business Writer Published: Dec 12, 2012 at 9:43 AM PDT Last Updated: Dec 12, 2012 at 10:21 AM PDT
Eli Lilly's experimental Alzheimer's drug has flashed potential to help with mild cases of the disease, but patients and doctors will have to wait a few more years to learn whether regulators will allow the drugmaker to sell it.
Health Lilly Alzheimer's drug shows some promise in study Lilly Alzheimer's drug shows some promise in study
By TOM MURPHY AP Business Writer Published: Aug 24, 2012 at 8:35 AM PDT
A possible Alzheimer's disease treatment from drugmaker Eli Lilly showed some promise in late-stage research, even though the drug failed to slow a form of mental decline in two separate studies of patients with the mind-robbing condition.
Business Insurer Aetna to buy Coventry in $5.7 billion deal Insurer Aetna to buy Coventry in $5.7 billion deal
By TOM MURPHY AP Business Writer Published: Aug 20, 2012 at 7:51 AM PDT
Aetna, one of the nation's biggest health insurers, staked a $5.7 billion claim in the burgeoning market for government-funded coverage Monday when it announced plans to buy fellow insurer Coventry Health Care.
Business WellPoint buying Amerigroup for $4.46 billion
By TOM MURPHY AP Business Writer Published: Jul 9, 2012 at 10:08 AM PDT
WellPoint Inc. will spend about $4.46 billion for Medicaid coverage provider Amerigroup Corp. in a deal that more than doubles the health insurer's enrollment in a market segment poised for expansion.
Business Walgreen to spend $6.7 billion on Alliance Boots stake Walgreen to spend $6.7 billion on Alliance Boots stake
By TOM MURPHY AP Business Writer Published: Jun 19, 2012 at 9:50 AM PDT
Walgreen Co. will pay $6.7 billion in cash and stock to buy a stake in European health and beauty retailer Alliance Boots, a deal that would give global clout to a U.S. drugstore chain struggling with slipping sales in its home market.
Business Big insurers to keep parts of health care law
By TOM MURPHY AP Business Writer Published: Jun 12, 2012 at 9:37 AM PDT
Some of the nation's biggest health insurers will keep some popular parts of President Barack Obama's health care overhaul even if the law fails to survive Supreme Court scrutiny later this month.
Health Survey: Health insurance costs surge in 2011 Survey: Health insurance costs surge in 2011
By TOM MURPHY AP Business Writer Published: Sep 27, 2011 at 10:54 AM PDT Last Updated: Sep 27, 2011 at 12:19 PM PDT
The cost of employer-sponsored health insurance surged this year, snapping a trend toward moderate growth, but experts say these increases may slow again in 2012.
Business Tyco plans to break up into 3 companies
By TOM MURPHY AP Business Writer Published: Sep 19, 2011 at 9:38 AM PDT
Tyco International Ltd. said Monday it plans to separate into three independent, publicly-traded companies, a move that will mark its second breakup since 2007.
National & World Survey: Employers consider ending health coverage
By TOM MURPHY AP Business Writer Published: Aug 24, 2011 at 8:10 AM PDT Last Updated: Aug 24, 2011 at 12:52 PM PDT
Nearly one of every 10 midsized or big employers expects to stop offering health coverage to workers once federal insurance exchanges start in 2014, according to a new survey from a large benefits consultant.
Business Lilly settles Zyprexa suit for $1.42 billion Lilly settles Zyprexa suit for $1.42 billion
By TOM MURPHY and MARLEY SEAMAN, AP Business Writers Published: Jan 15, 2009 at 10:21 AM PDT
Eli Lilly & Co. said Thursday it pleaded guilty to a charge that it illegally marketed the anti-psychotic drug Zyprexa for off-label use, and will pay a combined $1.42 billion to settle civil suits and end the criminal investigation.
Health Eli Lilly settles Zyprexa inquiries in 32 states Eli Lilly settles Zyprexa inquiries in 32 states
By TOM MURPHY and MARLEY SEAMAN AP Business Writers Published: Oct 7, 2008 at 9:26 PM PDT Last Updated: Nov 21, 2008 at 3:31 AM PDT
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.